Merus (NASDAQ:MRUS) Issues Quarterly Earnings Results

Merus (NASDAQ:MRUS - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.48, Zacks reports. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $9.14 million during the quarter, compared to the consensus estimate of $10.57 million.

Merus Price Performance

Shares of NASDAQ:MRUS traded down $1.62 during trading on Monday, reaching $45.47. 869,110 shares of the stock were exchanged, compared to its average volume of 631,086. The stock has a fifty day moving average of $42.04 and a two-hundred day moving average of $46.74. Merus has a 1-year low of $37.77 and a 1-year high of $61.61. The firm has a market cap of $3.11 billion, a price-to-earnings ratio of -11.51 and a beta of 1.11.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on MRUS shares. Wells Fargo & Company initiated coverage on Merus in a report on Friday, February 7th. They issued an "overweight" rating and a $91.00 target price on the stock. Citigroup increased their price target on Merus from $89.00 to $97.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Needham & Company LLC reduced their price target on shares of Merus from $85.00 to $83.00 and set a "buy" rating on the stock in a research report on Friday. Piper Sandler started coverage on shares of Merus in a research note on Thursday, February 13th. They issued an "overweight" rating and a $84.00 price target on the stock. Finally, William Blair restated an "outperform" rating on shares of Merus in a research note on Friday. One investment analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $85.77.

Remove Ads

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.